Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Mihael H. Polymeropoulos

Mihael H. Polymeropoulos

President, Chief Executive Officer, and Chairman, Vanda Pharmaceuticals

Appears in 1 story

Notable Quotes

"The BYSANTI approval marks a significant step forward, offering patients and providers a reliable new treatment grounded in extensive clinical heritage." — Mihael H. Polymeropoulos, upon Bysanti approval, February 2026

Stories

New antipsychotic approvals expand treatment options for schizophrenia and bipolar disorder

New Capabilities

Leading Vanda through dual drug launches in 2026

The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.

Updated May 29